The recent inclusion of CD26 as a putative leukemia stem cell marker in CML suggests that going forward, the CD34+/CD38–/CD26+ compartment may be most appropriate for identifying a resistance signature governing deep responses [22, 23]. The gene discussed is DPP4; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.